ADHD Clinical Trials 2024

ADHD Clinical Trials 2024

ADHD research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in ADD clinical trials today.

Trials for Attention Deficit Hyperactivity Disorder (ADHD) Patients

Trials for Attention Deficit Disorder Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to adhd

What are the top hospitals conducting adhd research?

In the realm of ADHD research and clinical trials, several hospitals have emerged as key players in advancing our understanding and treatment of this condition. Massachusetts General Hospital, located in Boston, leads the way with six ongoing ADHD trials and an impressive track record of 33 completed studies since their initial foray into ADHD research in 2001. Across the Atlantic, Hassman Research Institute based in Berlin has become a vital hub for ADHD trials as well. Though relatively new to the field with just four active trials and six overall studies since 2019, their dedication is undeniable.

Meanwhile, Alivation Research LLC located in Lincoln stands out with four active ADHD trials currently underway alongside seven previously conducted ones from their first recorded trial back in 2015. In Cincinnati's medical landscape, another institution making significant strides is Cincinnati Children's Hospital Medical Center where they boast involvement in four ongoing clinical tests alongside seventeen accomplished investigations dating back earlier to2003.The Seattle Children's Hospital also plays a crucial role within this sphere; while conducting three active ADHD trials at present it’s indeed noteworthy that theirs can be traced all the way back solely over eleven years ago to2009.

These hospitals signify not only breakthroughs but hope towards providing effective solutions for individuals affected by Attention Deficit Hyperactivity Disorder (ADHD). The collective efforts displayed among these leading institutions demonstrate unwavering commitment to unlocking greater insights into this neurodevelopmental disorder which affects millions worldwide. With each study undertaken comes potential advancements that could shape improved management strategies and brighter futures for those living with ADHD

Which are the best cities for adhd clinical trials?

When it comes to ADHD clinical trials, several cities have emerged as key players in the research field. Las Vegas, Nevada leads the pack with 12 active trials focusing on treatments like SPN-812 and Guanfacine hydrochloride (TAK-503). New york, New York follows closely behind with 10 ongoing studies examining therapies for adult ADHD patients such as centanafadine capsule. Boston, Massachusetts has 9 active trials investigating interventions like SMS Intervention and Solriamfetol 150 mg. Additionally, Cincinnati, Ohio is conducting 8 trials exploring treatments including Atomoxetine and Guanfacine hydrochloride (TAK-503), while Jacksonville, Florida offers 7 trials studying various ADHD therapies. These cities provide individuals with ADHD opportunities to participate in cutting-edge clinical research that could drive advancements in treatment options and improve quality of life.

Which are the top treatments for adhd being explored in clinical trials?

Exciting advancements are being made in the exploration of top treatments for ADHD through ongoing clinical trials. One notable intervention is SMS Intervention, which is currently being tested in three active trials and has a total of three ADHD trials since its initial listing in 2016. Additionally, there are two active trials investigating the effectiveness of ADHD Therapy, a treatment that entered the scene in 2023. Another intriguing avenue being explored is Tai Chi, with two active trials underway since its introduction to ADHD research in 2016. Finally, it's worth mentioning methylphenidate—a well-established player—which continues to show promise with two ongoing studies and an impressive track record of forty all-time ADHD trials dating back to 1998. As researchers delve deeper into these approaches, new possibilities may emerge for individuals affected by ADHD.

What are the most recent clinical trials for adhd?

Recent clinical trials have provided promising prospects for individuals with ADHD, offering potential advancements in treatment and care. Among these trials is the exploration of an experimental medication called CTx-1301, specifically a 37.5mg dexmethylphenidate tablet. The study aims to evaluate its efficacy in managing symptoms associated with ADHD, bringing hope to those seeking effective pharmaceutical interventions. Furthermore, another trial investigates the use of solriamfetol at a dose of 150 mg as a potential treatment option for ADHD patients. By delving into these innovative approaches through rigorous phases of testing, researchers aim to improve the lives and well-being of individuals living with this condition.

What adhd clinical trials were recently completed?

In the realm of ADHD research, recent clinical trials have reached significant milestones, bringing us closer to improved treatments for this neurodevelopmental disorder. In August 2021, Massachusetts General Hospital successfully completed a trial investigating the effectiveness of Solriamfetol 75 MG in managing ADHD symptoms. Similarly, Otsuka Pharmaceutical Development & Commercialization accomplished a trial testing Centanafadine in March 2021. These advancements highlight the commitment of researchers to finding novel solutions for individuals with ADHD and hold promise for enhancing their quality of life.